Compendium of Cancer Genome Aberrations

Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 754: Line 754:
|
|
|
|
| ||Yassmine Akkari (YA)
| ||Holly Drendel (HD)
|
|
|
|YA (prior AE)
|-
|-
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||
Line 762: Line 762:
|
|
|
|
| ||YA
| ||HD
|
|
|
|YA (prior AE)
|-
|-
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
Line 770: Line 770:
|
|
|PENDING
|PENDING
| ||YA
| ||HD
|
|
|
|YA (prior AE)
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee)
|    B-Lymphoblastic Leukemia/Lymphoma with  t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee)
Line 779: Line 779:
|PENDING
|PENDING
|
|
|YA
|HD
|
|
|
|YA (prior AE)
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||Marilena Melas + Yassmine Akkari
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||Marilena Melas + Yassmine Akkari
Line 787: Line 787:
|
|
|PENDING
|PENDING
| ||YA
| ||HD
|
|
|
|YA (prior AE)
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||Afia Hasnain + Yassmine Akkari
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||Afia Hasnain + Yassmine Akkari
Line 795: Line 795:
|
|
|PENDING
|PENDING
| ||YA
| ||HD
|
|
|
|YA (prior AE)
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  Hypodiploidy||Disease||Ashwini Yenamandra +
|    B-Lymphoblastic Leukemia/Lymphoma with  Hypodiploidy||Disease||Ashwini Yenamandra +
Line 806: Line 806:
|Complete
|Complete
|
|
|YA
|HD
|
|
|
|YA (prior AE)
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||Binu Porath + Linda Cooley
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||Binu Porath + Linda Cooley
Line 814: Line 814:
|
|
|PENDING
|PENDING
| ||YA
| ||HD
|
|
|
|YA (prior AE)
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||Binu Porath + Linda Cooley
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||Binu Porath + Linda Cooley
Line 822: Line 822:
|
|
|PENDING
|PENDING
| ||YA
| ||HD
|
|
|
|YA (prior AE)
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma,  BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera
|    B-Lymphoblastic Leukemia/Lymphoma,  BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera
Line 831: Line 831:
|Complete
|Complete
|
|
|YA
|HD
|
|
|
|YA (prior AE)
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||Holli Drendel
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||Holli Drendel
Line 839: Line 839:
|
|
|Complete
|Complete
| ||YA
| ||HD
|
|
|
|YA (prior AE)
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||Holli Drendel
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||Holli Drendel
Line 847: Line 847:
|
|
|PENDING
|PENDING
| ||YA
| ||HD
|
|
|
|YA (prior AE)
|-
|-
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
Line 858: Line 858:
|PENDING
|PENDING
|
|
|YA
|HD
|
|
|NON-WHO ENTITY
|YA (prior AE); NON-WHO ENTITY
|-
|-
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
Line 869: Line 869:
|PENDING
|PENDING
|
|
|YA
|HD
|
|
|NON-WHO ENTITY
|YA (prior AE); NON-WHO ENTITY
|-
|-
|B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
|B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
Line 880: Line 880:
|PENDING
|PENDING
|
|
|YA
|HD
|
|
|NON-WHO ENTITY
|YA (prior AE); NON-WHO ENTITY
|-
|-
|B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
|B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
Line 891: Line 891:
|PENDING
|PENDING
|
|
|YA
|HD
|
|
|NON-WHO ENTITY
|YA (prior AE); NON-WHO ENTITY
|-
|-
|B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
|B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
Line 902: Line 902:
|PENDING
|PENDING
|
|
|YA
|HD
|
|
|NON-WHO ENTITY
|YA (prior AE); NON-WHO ENTITY
|-
|-
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
Line 913: Line 913:
|PENDING
|PENDING
|
|
|YA
|HD
|
|
|NON-WHO ENTITY
|YA (prior AE); NON-WHO ENTITY
|-
|-
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang
Line 921: Line 921:
|
|
|PENDING
|PENDING
| ||YA
| ||HD
|
|
|
|YA (prior AE)
|-
|-
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang
Line 929: Line 929:
|
|
|PENDING
|PENDING
| ||YA
| ||HD
|
|
|2021 template added
|YA (prior AE); 2021 template added
|-
|-
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
Line 937: Line 937:
|
|
|PENDING
|PENDING
| ||YA
| ||HD
|
|
|2021 template added
|YA (prior AE); 2021 template added
|-
|-
| || ||
| || ||
Line 953: Line 953:
|
|
|
|
| ||Snehal Patel (SP)
| ||Shivani Golem (SG)
|
|
|
|SP (prior AE)
|-
|-
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||
Line 962: Line 962:
|
|
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|       Monoclonal B-cell  Lymphocytosis||Disease||Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
|       Monoclonal B-cell  Lymphocytosis||Disease||Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
Line 971: Line 971:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|2021 template added
|SP (prior AE), 2021 template added
|-
|-
|B-cell Prolymphocytic Leukemia||Disease||
|B-cell Prolymphocytic Leukemia||Disease||
Line 980: Line 980:
|
|
|
|
|SP
|SG
|
|
|2021 template added; No longer an entity
|SP (prior AE); 2021 template added; No longer an entity
|-
|-
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
Line 989: Line 989:
|Complete
|Complete
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|Hairy Cell Leukemia||Disease||Snehal Patel
|Hairy Cell Leukemia||Disease||Snehal Patel
Line 998: Line 998:
|Complete
|Complete
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
Line 1,007: Line 1,007:
|Complete
|Complete
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease||Snehal Patel
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease||Snehal Patel
Line 1,016: Line 1,016:
|Complete
|Complete
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|    Hairy Cell Leukemia  Variant||Disease||Snehal Patel
|    Hairy Cell Leukemia  Variant||Disease||Snehal Patel
Line 1,025: Line 1,025:
|Complete
|Complete
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|Lymphoplasmacytic Lymphoma||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
|Lymphoplasmacytic Lymphoma||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
Line 1,034: Line 1,034:
|PENDING review  by FQR
|PENDING review  by FQR
|
|
|SP
|SG
|
|
|2021 template added
|SP (prior AE); 2021 template added
|-
|-
|   Waldenstrom  Macroglobulinemia||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
|   Waldenstrom  Macroglobulinemia||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
Line 1,043: Line 1,043:
|PENDING review  by FQR
|PENDING review  by FQR
|
|
|SP
|SG
|
|
|2021 template added
|SP (prior AE); 2021 template added
|-
|-
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
Line 1,051: Line 1,051:
|
|
|
|
| ||SP
| ||SG
|
|
|
|SP (prior AE)
|-
|-
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
Line 1,059: Line 1,059:
|
|
|
|
| ||SP
| ||SG
|
|
|
|SP (prior AE)
|-
|-
|    Mu Heavy Chain  Disease||Disease||
|    Mu Heavy Chain  Disease||Disease||
Line 1,067: Line 1,067:
|
|
|
|
| ||SP
| ||SG
|
|
|
|SP (prior AE)
|-
|-
|   Gamma Heavy Chain  Disease||Disease||Manisha Sutariya
|   Gamma Heavy Chain  Disease||Disease||Manisha Sutariya
Line 1,075: Line 1,075:
|
|
|Complete
|Complete
|5/26/2021||SP
|5/26/2021||SG
|
|
|
|SP (prior AE)
|-
|-
|    Alpha Heavy Chain  Disease||Disease||
|    Alpha Heavy Chain  Disease||Disease||
Line 1,083: Line 1,083:
|
|
|
|
| ||SP
| ||SG
|
|
|
|SP (prior AE)
|-
|-
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
Line 1,092: Line 1,092:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease||Zhenya Tang
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease||Zhenya Tang
Line 1,101: Line 1,101:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|    Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
|    Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
Line 1,110: Line 1,110:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|    Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear
|    Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear
Line 1,119: Line 1,119:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|    Plasmacytoma||Disease||Zhenya Tang
|    Plasmacytoma||Disease||Zhenya Tang
Line 1,128: Line 1,128:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||Chen Yang, MD, PhD
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||Chen Yang, MD, PhD
Line 1,136: Line 1,136:
|
|
|Complete
|Complete
|09/10/2022||SP
|09/10/2022||SG
|
|
|
|SP (prior AE)
|-
|-
|           Primary  Amyloidosis||Disease||Heather E. Williams, PhD
|           Primary  Amyloidosis||Disease||Heather E. Williams, PhD
Line 1,144: Line 1,144:
|
|
|?PENDING
|?PENDING
| ||SP
| ||SG
|
|
|
|SP (prior AE)
|-
|-
|           Light Chain and Heavy Chain Deposition Disease||Disease||Chen Yang, MD, PhD
|           Light Chain and Heavy Chain Deposition Disease||Disease||Chen Yang, MD, PhD
Line 1,152: Line 1,152:
|
|
|Complete
|Complete
|10/15/2022||SP
|10/15/2022||SG
|
|
|
|SP (prior AE)
|-
|-
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
Line 1,160: Line 1,160:
|9/15/2021
|9/15/2021
|PENDING
|PENDING
| ||SP
| ||SG
|
|
|
|SP (prior AE)
|-
|-
|         POEMS Syndrome||Disease||Sohini Anand, MBBS, and Tharanga Niroshini Senaratne, PhD
|         POEMS Syndrome||Disease||Sohini Anand, MBBS, and Tharanga Niroshini Senaratne, PhD
Line 1,168: Line 1,168:
|
|
|?PENDING
|?PENDING
| ||SP
| ||SG
|
|
|
|SP (prior AE)
|-
|-
|         TEMPI Syndrome||Disease||Sohini Anand, MBBS
|         TEMPI Syndrome||Disease||Sohini Anand, MBBS
Line 1,176: Line 1,176:
|
|
|?PENDING
|?PENDING
| ||SP
| ||SG
|
|
|
|SP (prior AE)
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
Line 1,185: Line 1,185:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|2021 template added
|SP (prior AE); 2021 template added
|-
|-
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
Line 1,193: Line 1,193:
|
|
|Complete
|Complete
|5/28/2021||SP
|5/28/2021||SG
|
|
|
|SP (prior AE)
|-
|-
|    Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|    Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
Line 1,202: Line 1,202:
|Complete
|Complete
|11/11/2020
|11/11/2020
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|Follicular Lymphoma||Disease||Ruthann Pfau
|Follicular Lymphoma||Disease||Ruthann Pfau
Line 1,211: Line 1,211:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|    Testicular Follicular Lymphoma||Disease||Ruthann Pfau
|    Testicular Follicular Lymphoma||Disease||Ruthann Pfau
Line 1,220: Line 1,220:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|    In Situ Follicular Neoplasia||Disease||Ruthann Pfau
|    In Situ Follicular Neoplasia||Disease||Ruthann Pfau
Line 1,229: Line 1,229:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|    Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau
|    Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau
Line 1,238: Line 1,238:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
Line 1,247: Line 1,247:
|Complete
|Complete
|8/16/2020
|8/16/2020
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid
Line 1,255: Line 1,255:
|9/30/20
|9/30/20
|Complete
|Complete
|5/26/2021||SP
|5/26/2021||SG
|
|
|
|SP (prior AE)
|-
|-
|Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem
|Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem
Line 1,264: Line 1,264:
|Complete
|Complete
|09/10/2022
|09/10/2022
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|Mantle Cell Lymphoma||Disease||Mahsa Khanlari
|Mantle Cell Lymphoma||Disease||Mahsa Khanlari
Line 1,273: Line 1,273:
|PENDING
|PENDING
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Tsigab Hagos (trainee)/Shashirekha.Shetty
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Tsigab Hagos (trainee)/Shashirekha.Shetty
Line 1,282: Line 1,282:
|Pending
|Pending
|
|
|SP
|SG
|
|
|
|SP (prior AE)
|-
|-
|    In Situ Mantle Cell  Neoplasia||Disease||Rina Kansal, MD
|    In Situ Mantle Cell  Neoplasia||Disease||Rina Kansal, MD
Line 1,291: Line 1,291:
|Complete
|Complete
|7/26/2022
|7/26/2022
|SP
|SG
|
|
|2021 template added
|SP (prior AE); 2021 template added
|-
|-
| || ||
| || ||
Retrieved from "https://test.ccga.io/index.php/Volunteer_Assignments_and_Opportunities"